Exozymes Inc.
eXoZymes (Nasdaq: EXOZ) develops cell-free biomanufacturing systems using AI-assisted engineered enzymes, called exozymes, to produce chemicals outside living cells. Its platform combines engineered enzymes, feedstocks and cofactors in bioreactors to make small molecules, with an initial focus on nutraceutical… From the company’s description.
In fiscal 2025, Exozymes Inc. reported a net loss of $9.16M. Operations used $6.50M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Exozymes Inc. does
In the company’s own words
eXoZymes (Nasdaq: EXOZ) develops cell-free biomanufacturing systems using AI-assisted engineered enzymes, called exozymes, to produce chemicals outside living cells. Its platform combines engineered enzymes, feedstocks and cofactors in bioreactors to make small molecules, with an initial focus on nutraceutical ingredients that may also have pharmaceutical applications. The company is developing N-trans-caffeoyltyramine (NCT) for potential nutraceutical use and possible pharmaceutical derivatives, and is also pursuing isobutanol for biofuels and other applications. eXoZymes is a pre-revenue development-stage company that seeks to commercialize applications through subsidiaries, joint ventures and licensing, generally working with partners that can contribute manufacturing capabilities, market access or financing. Its NCT commercialization subsidiary, NCTX, is intended to develop and commercialize NCT as a branded nutraceutical ingredient. The company has received $17.7 million in grants from its inception through 2025, including funding for research into isobutanol, cannabinoids, terpenes and cofactors.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- MONROVIA, CA
- Fiscal year end
- December
- CIK
- 2010788
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Exozymes Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Exozymes Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Exozymes Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Exozymes Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Exozymes Inc.'s last four quarterly filings that the numbers alone won't show?”